|
摘要：
|
The failure of many new , mostly biologic, drugs to meet their primary end points in double- blind clinical trials in patients with systemic lupus erythematosus (SLE) has caused a profound sense of disappointment among both physicians and patients. Arguably , the success of B cell depletion with rit...
|